{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:21:33Z","timestamp":1788481293551,"version":"build-2803163510"},"reference-count":33,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2012,12,31]],"date-time":"2012-12-31T00:00:00Z","timestamp":1356912000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100001275","name":"Oak Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001275","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NHS"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2013,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Therapy for high\u2010risk neuroblastoma is intensive and multimodal, and significant long\u2010term adverse effects have been described. The aim of this study was to identify the nature and severity of late complications of metastatic neuroblastoma survivors included in the ENSG5 clinical trial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Procedure<\/jats:title><jats:p>The trial protocol included induction chemotherapy (randomized \u201cStandard\u201d OPEC\/OJEC vs. \u201cRapid\u201d COJEC), surgery of primary tumor and high\u2010dose melphalan with stem cell rescue. Two hundred and sixty\u2010two children were randomized, 69 survived &gt;5 years, and 57 were analyzed. Data were obtained from the ENSG5 trial database and verified with questionnaires sent to participating centers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Median follow\u2010up was 12.9 (6.9\u201316.5) years. No differences were found in late toxicities between treatment arms. Twenty\u2010eight children (49.1%) developed hearing loss. Nine patients (15.8%) developed glomerular filtration rate &lt;80\u2009ml\/min\/1.73\u2009m<jats:sup>2<\/jats:sup>, but no cases of chronic renal failure were documented. Endocrine complications (28.1% of children) included mainly hypogonadism and delayed growth. Four children developed second malignancies, three of them 5 years after diagnosis: one osteosarcoma, one carcinoma of the parotid gland and one ependymoma. There were no hematological malignancies or deaths in remission.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study analyzed a wide cohort of high\u2010risk neuroblastoma survivors from a multi\u2010institutional randomized trial and established the profile of long\u2010term toxicity within the setting of an international clinical trial. Pediatr Blood Cancer 2013; 60: 1135\u20131140. \u00a9 2012 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.24452","type":"journal-article","created":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T20:16:07Z","timestamp":1357071367000},"page":"1135-1140","source":"Crossref","is-referenced-by-count":46,"title":["Long\u2010term follow\u2010up of children with high\u2010risk neuroblastoma: The ENSG5 trial experience"],"prefix":"10.1002","volume":"60","author":[{"given":"Lucas","family":"Moreno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sucheta J.","family":"Vaidya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Ross","family":"Pinkerton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian J.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Imeson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Machin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D. J.","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the European Neuroblastoma Study Group and the Children's Cancer and Leukaemia Group (CCLG) (formerly UKCCSG)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,12,31]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60983-0"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.09.016"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001527"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.9990"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199910143411601"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.8925"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20219"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.05.191"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.6785"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0911123"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3835(03)00076-4"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/1096-911X(20010101)36:1<235::AID-MPO1057>3.0.CO;2-N"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-21"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20331"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.23036"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6690300"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21931"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.12.3880"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.7235"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.02.036"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007-0178"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705809"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.05.6986"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21683"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djp230"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70069-X"},{"key":"e_1_2_6_28_2","unstructured":"CTEP.Common Terminology Criteria for Adverse Events v3.0 (CTCAE).2006.http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf[Accessed November 27 2012]."},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950190415"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2009.06.032"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702021"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2005.10.020"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.11455"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11167"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.24452","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.24452","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.24452","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T08:05:35Z","timestamp":1700640335000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.24452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,31]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["10.1002\/pbc.24452"],"URL":"https:\/\/doi.org\/10.1002\/pbc.24452","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,31]]}}}